Family of PFKFB3 Inhibitors with Anti-Cancer Activities (07010)

Family of highly specific small molecules; May suppress metabolism of cancer cells and proliferation of multiple cancer types; High oral bioavailability. There are an estimated 15 million people living with cancer in the U.S. alone. With a 5year survival rate of only 67%, cancer is among the leading causes of death worldwide. Due to the disease’s high prevalence and mortality, there is an urgent need for effective methods to treat it. To address that need, researchers at the University of Louisville have developed 6phosphofructo-2-kinase/fructose-2,6bisphosphatase 3 (PFKFB3) inhibitors that may be used as anti-cancer therapeutics. By inhibiting PFKFB3, the compounds suppress cancer cells’ metabolism, thereby impairing the growth of tumors. The compounds have high oral bioavailability and have been shown to successfully suppress growth of tumors in mice and in human cancer cells in vitro. Rob Smith robert.smith.6@louisville.edu 502-852-3027

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More